2021
The Role of Immune Checkpoint Therapy in Propagating Neurologic Immune-Related Adverse Events: Inducing or "Unmasking" Autoimmunity?
Gardin T, Longbrake EE. The Role of Immune Checkpoint Therapy in Propagating Neurologic Immune-Related Adverse Events: Inducing or "Unmasking" Autoimmunity? Neurology 2021, 96: 733-734. PMID: 33727404, DOI: 10.1212/wnl.0000000000011812.Peer-Reviewed Original Research
2020
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity
Longbrake EE, Mao-Draayer Y, Cascione M, Zielinski T, Bame E, Brassat D, Chen C, Kapadia S, Mendoza JP, Miller C, Parks B, Xing D, Robertson D. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Multiple Sclerosis Journal 2020, 27: 883-894. PMID: 32716690, PMCID: PMC8023410, DOI: 10.1177/1352458520937282.Peer-Reviewed Original ResearchConceptsDelayed-release dimethyl fumarateAbsolute lymphocyte countT cellsMedian absolute lymphocyte countEffector memory T cellsDimethyl fumarate treatmentPhase 3b studyTotal T cellsAdverse event ratesMemory T cellsProtective humoral immunityForms of MSDMF BIDLymphocyte subsetsAdverse eventsLymphocyte countTotal IgAImmune environmentImmunoglobulin levelsNaive CD4Sustained efficacyHumoral immunityFumarate treatmentSubclass levelsCount changes
2018
Effectiveness of alternative dose fingolimod for multiple sclerosis
Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, Berkovich R, Ge L, Bacon TE, Kister I. Effectiveness of alternative dose fingolimod for multiple sclerosis. Neurology Clinical Practice 2018, 8: 102-107. PMID: 29708225, PMCID: PMC5914753, DOI: 10.1212/cpj.0000000000000434.Peer-Reviewed Original ResearchProportion of patientsDaily doseMultiple sclerosisAlternate doseAdverse eventsDisease activityProfound lymphopeniaContrast-enhancing MRI lesionsAlternate dosingLiver function abnormalitiesClass IV evidenceDaily oral medicationContrast-enhancing lesionsBetter disease controlBreakthrough diseaseMRI lesionsRadiologic outcomesFunction abnormalitiesMost patientsOral medicationsRelapse rateFrequent dosingObservational studyFingolimodHigh risk